Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage
Article first published online: 11 FEB 2008
© 2008 The Authors
Australian and New Zealand Journal of Obstetrics and Gynaecology
Volume 48, Issue 1, pages 12–16, February 2008
How to Cite
WELSH, A., McLINTOCK, C., GATT, S., SOMERSET, D., POPHAM, P. and OGLE, R. (2008), Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Australian and New Zealand Journal of Obstetrics and Gynaecology, 48: 12–16. doi: 10.1111/j.1479-828X.2007.00823.x
- Issue published online: 11 FEB 2008
- Article first published online: 11 FEB 2008
- Received 03 July 2007; accepted 16 November 2007.
Recombinant activated factor VII (rFVIIa) is emerging as a novel therapy for the treatment of life or fertility-threatening post-partum haemorrhage (PPH) unresponsive to standard therapy that in some cases may prevent the need for peripartum hysterectomy. The level of evidence to date for use of rFVIIa in PPH is limited to case reports and case series with one nonrandomised study. No high-quality randomised controlled trials have been published at this stage, precluding a quality systematic review. Guidelines have been published for the use of rFVIIa in non-obstetric haemorrhage, though to date none are available for PPH. A multidisciplinary group of Australian and New Zealand clinicians from the fields of obstetrics, anaesthesia and haematology, who have both clinical experience in and/or knowledge of rFVIIa was convened by the manufacturer. This group produced an opinion and guideline based on their experience and the published international literature on the use of rFVIIa. This is intended to be used as a guideline and algorithm for the use of rFVIIa, though any use should be tailored to local practice and resources.